Combined Treatment with Anisodamine and Neostigmine Inhibits Joint Inflammation in Collagen‐Induced Arthritis Mice

Jian Zhou,Ke Peng,Huan Gui,Bo‐Zong Shao,Chong Liu

DOI: https://doi.org/10.1111/cns.12213

2014-01-01

CNS Neuroscience & Therapeutics

Abstract:Rheumatoid arthritis (RA) is a complicated and treatment refractory autoimmune disease that is characterized by a chronic inflammatory infiltration of immune cells 1. The central nervous system plays an important role in limiting inflammatory responses via an inflammatory reflex of the vagus nerve termed as “the cholinergic antiinflammatory pathway” 2. Acetylcholine, the principal neurotransmitter of the vagus nerve, interacts with α7 nicotinic acetylcholine receptor (α7nAChR) expressed on macrophages and other cells and could inhibit the production of proinflammatory cytokines such as TNFα, interleukin (IL)-1β, and IL-6. Decreased level of vagus nerve activity is correlated with increased serum concentration of late-phase inflammation cytokine high-mobility group box chromosomal protein 1 in patients with RA. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis (CIA) in mice. Lack of α7nAChR aggravates the development of CIA 3. Our previous studies showed that anisodamine blocks muscarinic receptors, and thus promotes more endogenous acetylcholine to bind with α7nAChR 4. Neostigmine, a cholinesterase inhibitor, produces antiinflammatory actions through increasing the concentration of endogenous acetylcholine 5. A combination of anisodamine and neostigmine augments the antishock efficacy through activating the α7nAChR-dependent cholinergic antiinflammatory pathway and reduces the infarct size in rats subjected to middle cerebral artery occlusion 6. In this study, we evaluated the therapeutical value of anisodamine/neostigmine combination in CIA model 7. CIA was induced in DBA/1 mice which were immunized with 100 μg bovine type II collagen (Chondrex, Redmond, WA, USA) and emulsified with an equal volume of complete Freund's adjuvant (Chondrex). The day of the first immunization was defined as day 0. A boost injection of bovine type II collagen of the same amount was carried out on day 21. Mice received daily i.p. injection of anisodamine (25 mg/kg) and neostigmine (50 μg/kg) from the day of the boost immunization for 10 days. Immunized mice receiving daily saline injection were used as a control. Arthritic symptoms were evaluated according to previously reported 8. The sum of the scores in the two hind limbs was used as the arthritic score. Blood samples were collected 5 days after the last treatment, and type II collagen-specific antibodies and inflammatory cytokines were measured using commercial ELISA kits (R&D system, Research & Development, San Diego, CA, USA) 9, 10. All results are expressed as the mean ± SD. The Mann–Whitney U-test was used to analyze the arthritic severity. Cytokines and antibody levels were analyzed using the Student's t-test. Statistical significance was set at P < 0.05. A combined treatment significantly reduced arthritis score and joint swelling (P < 0.05 vs. vehicle; Figure 1A), starting from day 23 and throughout the evaluation period. Combined treatment also significantly inhibited weight loss (Figure 1B). The immunization increased the serum concentration of anti-type II collagen-specific antibodies (IgG, IgG1, and IgG2a). Combined treatment significantly decreased the serum levels of IgG and IgG2a, but not IgG1 (Figure 2A–C). Combined treatment also significantly decreased the serum level of TNFα, IL-1β, and IL-6 (Figure 2D–F). Collectively, a combination of anisodamine and neostigmine could decrease arthritic index, reduce joint swelling, and inhibit weight loss. Combined treatment also decreased the serum levels of anti-type II collagen-specific antibodies and inflammatory cytokines in CIA mice. Our findings may have important implications toward the development of new treatment strategies for RA, but such a possibility requires further investigation. This work was supported by a grant from the Shanghai Natural Science Foundation of China (13ZR1448400). The authors declare no conflict of interest.